About 180 people will get brain scans while choosing between food and money, to see if GLP-1 use changes how the brain handles instant rewards.
Recap by typeshit. Full story at KZTV10.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
About 180 people will get brain scans while choosing between food and money, to see if GLP-1 use dulls the pull of instant rewards.
The study will scan the brains of about 180 people as they make food and money choices, looking for changes in how the reward system handles instant gratification.
Loading…